Stage IV colon cancer patients without DENND2D expression benefit more from neoadjuvant chemotherapy

Stage IV colon cancer patients without DENND2D expression benefit more from neoadjuvant chemotherapy

Abstract According to the EPOC study, chemotherapy could improve 5-year disease-free survival of stage IV colon cancer patients by 8.1%. However, more molecular biomarkers are required to identify patients who need neoadjuvant chemotherapy. DENND2D expression was evaluated by immunohistochemistry in...

Full description

Bibliographic Details
Main Authors: Wen-juan Ma, Yukun Chen, Jian-hong Peng, Chaoming Tang, Ling Zhang, Min Liu, Shanshan Hu, Haineng Xu, Hua Tan, Yangkui Gu, Zhi-zhong Pan, Gong Chen, Zhong-guo Zhou, Rong-xin Zhang
Format: Article
Language:English
Published: Nature Publishing Group 2022-05-01
Series:Cell Death and Disease
Online Access:https://doi.org/10.1038/s41419-022-04885-8

Internet

https://doi.org/10.1038/s41419-022-04885-8

Similar Items